Reviva Pharmaceuticals Holdings, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Apr 15, 2024 and accepted by EDGAR at Apr 15, 2024, 08:22 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-01-01 to 2023-12-31 | $31.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$39.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $16.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$39.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$1.65 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$28.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-12-31 | $23.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Total assets | At period end2023-12-31 | $23.7m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $17.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $18.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | $5.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-24-011955. Last ingested by Listed: Oct 29, 2026, 16:33 ET. Listed shows no prices and gives no investment advice.